3 Contract Manufacturer, Emerging Market Generic and Device Stocks With a Strong Future Roadmap: Akums Drugs and Pharmaceuticals, Lincoln Pharmaceuticals and Poly Medicure

Contract manufacturer, emerging market generic and device stocks give investors exposure to manufacturing, medicines and devices that drug brands, doctors and hospitals use. Contract orders, export volumes and device sales decide how much of that demand turns into profit.

This list covers three contract manufacturer, emerging market generic and device stocks: Akums Drugs and Pharmaceuticals for contract development and manufacturing of pharmaceutical and nutraceutical products, Lincoln Pharmaceuticals for formulations sold in India and emerging export markets and Poly Medicure for medical devices such as infusion sets, needles, catheters and dialysis products. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Contract Manufacturer, Emerging Market Generic and Device Stocks?

Contract manufacturer, emerging market generic and device stocks are shares of companies that manufacture for drug brands, sell formulations or make devices. Results depend on contract orders, export volumes and device sales, so growth and margins separate the stronger names.

Contract Manufacturer, Emerging Market Generic and Device Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three contract manufacturer, emerging market generic and device stocks as of the 13 Oct 2026 close.

Among healthcare stocks, Akums trades at a premium to the industry P/E, while Lincoln Pharma and Poly Medicure trade at a discount.

Why Do Contract Manufacturer, Emerging Market Generic and Device Stocks Have a Strong Roadmap in India?

Contract manufacturer, emerging market generic and device stocks have a strong roadmap in India because outsourced drug making, emerging market demand and hospital use of medical devices keep lifting these healthcare firms. Three drivers stand out.

• Outsourced making: Brands hand manufacturing to specialist plants.
• Emerging markets: Export formulations reach growing patient bases.
• Hospital supplies: Devices are used in every ward.

Akums Drugs and Pharmaceuticals: Contract Manufacturing Anchors the Roadmap

Akums' roadmap rests on contract development and manufacturing of pharmaceutical and nutraceutical products, with outsourcing demand from drug companies supporting orders.

Revenue grew from Rs 3,694.52 crore in FY22 to Rs 4,487.74 crore in FY26, a 21.5% rise, and FY26 revenue was 7.6% higher than FY25. FY26 net profit was Rs 256.40 crore. In Q1 FY27, revenue grew 13.9% to Rs 1,197.01 crore, and net profit rose 56.1% to Rs 100.98 crore. Operating margin was 14.47% in FY26 and 17.58% in Q1 FY27 against 15.20% a year earlier.

Debt to equity is 0.05 and return on equity is 7.70%. FY26 operating cash flow was Rs 1,181.20 crore against capital expenditure of Rs 230.53 crore. Akums paid a dividend of Rs 3 per share for FY26, a yield of 0.37%. At a P/E of 42.26 against an industry P/E of 37.59, the stock trades above its industry multiple.

What to watch: Return on equity of 7.70% is modest.

Lincoln Pharmaceuticals: Formulations for India and Export Markets Build the Next Leg

Lincoln Pharma's roadmap rests on formulations sold in India and emerging export markets, with a broad product list supporting revenue.

Revenue grew from Rs 482.12 crore in FY22 to Rs 704.48 crore in FY26, a 46.1% rise, and FY26 revenue was 9.1% higher than FY25. FY26 net profit rose 6.7% to Rs 87.89 crore. Over four years, net profit rose from Rs 69.36 crore in FY22 to Rs 87.89 crore. In Q1 FY27, revenue grew 19.0% to Rs 201.54 crore, and net profit rose 30.9% to Rs 36.23 crore.

Debt to equity is 0.01 and return on equity is 11.60%. The dividend yield is 0.32%. At a P/E of 11.64 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The P/E of 11.64 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Poly Medicure: Medical Devices Build the Next Leg

Poly Medicure's roadmap rests on medical devices such as infusion sets, needles, catheters and dialysis products sold in India and many export markets, with rising healthcare consumption and export demand supporting growth.

Revenue grew from Rs 960.97 crore in FY22 to Rs 1,995.34 crore in FY26, a 107.6% rise, and FY26 revenue was 13.4% higher than FY25. FY26 net profit was Rs 320.73 crore. In Q1 FY27, revenue grew 25.5% to Rs 558.79 crore. Operating margin was 27.65% in FY26.

Debt to equity is 0.11 and return on equity is 10.37%. FY26 operating cash flow was Rs 246.37 crore against capital expenditure of Rs 308.39 crore. Poly Medicure paid a dividend of Rs 3.5 per share for FY26, a yield of 0.22%. At a P/E of 51.87 against an industry P/E of 62.79, the stock trades below its industry multiple.

What to watch: The P/E of 51.87 against an industry P/E of 62.79 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Best Contract Manufacturer, Emerging Market Generic and Device Stocks in India: Akums vs Lincoln Pharma vs Poly Medicure on Key Financials

Among the best contract manufacturer, emerging market generic and device stocks in India, Akums leads on dividend yield; Lincoln Pharma leads on return on equity and the lowest P/E; Poly Medicure leads on FY26 revenue growth and Q1 FY27 revenue growth. The table puts the numbers side by side.

Healthcare earnings follow contract orders, export volumes and device sales, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Contract Manufacturer, Emerging Market Generic and Device Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen contract manufacturer, emerging market generic and device stocks and shortlist contract manufacturer, emerging market generic and device stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check revenue growth, operating margin and return on equity together.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these contract manufacturer, emerging market generic and device stocks

Risks to Consider Before Investing in Contract Manufacturer, Emerging Market Generic and Device Stocks

• Pricing rules: Price controls can affect margins.
• Competition: Rival brands and providers can pressure growth.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Akums, Lincoln Pharma and Poly Medicure live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare stocks cover contract manufacturing, emerging market formulations and medical devices. Akums leads on dividend yield; Lincoln Pharma leads on return on equity and the lowest P/E; Poly Medicure leads on FY26 revenue growth and Q1 FY27 revenue growth.

Across contract manufacturer, emerging market generic and device stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the contract manufacturer, emerging market generic and device stocks to buy discussed here.

FAQs on Contract Manufacturer, Emerging Market Generic and Device Stocks

Which are the best contract manufacturer, emerging market generic and device stocks in India with a strong roadmap?

Ans. Akums Drugs and Pharmaceuticals, Lincoln Pharmaceuticals and Poly Medicure stand out for their roadmaps in contract manufacturing, emerging market formulations and medical devices. FY26 revenue growth was 7.6% at Akums, 9.1% at Lincoln Pharma and 13.4% at Poly Medicure, and return on equity ranges from 7.70% to 11.60%.

Is Akums Drugs and Pharmaceuticals a good stock to buy now?

Ans. Akums Drugs and Pharmaceuticals has a debt to equity ratio of 0.05, a return on equity of 7.70% and a P/E of 42.26 against an industry P/E of 37.59. Valuation, growth and pricing rules move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Akums, Lincoln Pharma and Poly Medicure?

Ans. The P/E ratio is 42.26 for Akums (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 51.87 for Poly Medicure (industry 62.79). Only Akums trades at or above the industry multiple.

Which of these contract manufacturer, emerging market generic and device stocks has the highest return on equity?

Ans. Lincoln Pharmaceuticals has the highest return on equity at 11.60%, followed by Poly Medicure at 10.37% and Akums Drugs and Pharmaceuticals at 7.70%.

What are the risks of investing in contract manufacturer, emerging market generic and device stocks?

Ans. The main risks are pricing rules, competition and quarterly trends. Price controls can affect margins.

How did Akums, Lincoln Pharma and Poly Medicure perform in Q1 FY27?

Ans. Akums Drugs and Pharmaceuticals reported revenue of Rs 1,197.01 crore, up 13.9% year on year, and net profit rose 56.1% to Rs 100.98 crore. Lincoln Pharmaceuticals reported revenue of Rs 201.54 crore, up 19.0% year on year, and net profit rose 30.9% to Rs 36.23 crore. Poly Medicure reported revenue of Rs 558.79 crore, up 25.5% year on year.

Do contract manufacturer, emerging market generic and device stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.37% for Akums, 0.32% for Lincoln Pharma and 0.22% for Poly Medicure, based on dividends declared for FY26.

How can I invest in contract manufacturer, emerging market generic and device stocks in India?

Ans. You can buy contract manufacturer, emerging market generic and device stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.